Current Report Filing (8-k)
July 15 2022 - 8:02AM
Edgar (US Regulatory)
0001642380
false
0001642380
2022-07-15
2022-07-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (date of earliest event reported): July 15, 2022
Oncocyte
Corporation
(Exact
name of registrant as specified in its charter)
California |
|
1-37648 |
|
27-1041563 |
(State
or other jurisdiction |
|
(Commission |
|
(IRS
Employer |
of
incorporation) |
|
File
Number) |
|
Identification
No.) |
15
Cushing
Irvine,
California 92618
(Address
of principal executive offices)
(949)
409-7600
(Registrant’s
telephone number, including area code)
Securities
registered pursuant to Section 12(b) of the Exchange Act:
Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
Common
Stock, no par value |
|
OCX |
|
The
Nasdaq Stock Market LLC |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Forward-Looking
Statements
Any
statements that are not historical fact (including, but not limited to statements that contain words such as “may,” “will,”
“believes,” “plans,” “intends,” “anticipates,” “expects,” “estimates”)
should be considered to be forward-looking statements. Factors that could cause actual results to differ materially from the results
anticipated in these forward-looking statements are contained in Oncocyte Corporation’s Annual Report on Form 10-K filed with the
Securities and Exchange Commission (“SEC”) under the heading “Risk Factors” and in other filings that Oncocyte
may make with the SEC. Undue reliance should not be placed on these forward-looking statements which speak only as of the date they are
made, and the facts and assumptions underlying these statements may change. Except as required by law, Oncocyte disclaims any intent
or obligation to update these forward-looking statements.
References
to “Oncocyte,” the “Company,” we,” “us,” and “our” are references to Oncocyte Corporation.
Item
7.01 - Regulation FD Disclosure.
On
July 15, 2022, Oncocyte will deliver a presentation at its 2022 Annual Meeting of Shareholders, which will also be made available on
its website. A copy of the presentation is being furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
The
information contained in this Item, including the Exhibit attached hereto, is being furnished and shall not be deemed “filed”
for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the
Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing.
Item
9.01 - Financial Statements and Exhibits.
Exhibit
Number |
|
Description |
99.1 |
|
Annual Meeting Presentation |
104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
ONCOCYTE
CORPORATION |
|
|
|
Date:
July 15, 2022 |
By: |
/s/
Ronald Andrews |
|
|
Ronald
Andrews |
|
|
Chief
Executive Officer |
Oncocyte (NASDAQ:OCX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oncocyte (NASDAQ:OCX)
Historical Stock Chart
From Sep 2023 to Sep 2024